financetom
Business
financetom
/
Business
/
Bankwell Financial's Q2 net income rises to $9.1 mln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bankwell Financial's Q2 net income rises to $9.1 mln
Jul 28, 2025 4:30 AM

Overview

* Bankwell Financial ( BWFG ) Q2 revenue beats analyst expectations, driven by reduced funding costs

* Net income for Q2 rises to $9.1 mln, reflecting improved profitability

* Company declares $0.20 per share dividend, updates 2025 guidance for income growth

Outlook

* Bankwell updates 2025 net interest income guidance to $97 - $98 mln

* Company reiterates 2025 noninterest income guidance of $7 - $8 mln

* Bankwell increases 2025 noninterest expense guidance to $58 - $59 mln

* Company anticipates deposit growth boost from new banking teams in 2026

Result Drivers

* NET INTEREST MARGIN - Increased to 3.10% due to improved funding costs and strategic repricing of deposits

* SBA LOAN GROWTH - SBA loan originations contributed to $24 mln net loan growth and $1.5 mln in non-interest income

* DEPOSIT STRATEGY - Addition of five deposit-focused private banking teams expected to boost deposit growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $25.95 $24.30

Revenue mln mln (3

Analysts

)

Q2 EPS $1.15

Q2 Net $9.10

Income mln

Q2 Net $23.94

Interest mln

Income

Q2 Net 3.1%

Interest

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for Bankwell Financial Group Inc ( BWFG ) is $40.25, about 7.1% above its July 25 closing price of $37.39

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test
Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test
Jun 14, 2024
08:22 AM EDT, 06/14/2024 (MT Newswires) -- Renalytix ( RNLX ) said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier. As of Aug. 1, the test will be covered by Medicare for patients with diagnosed type 2 diabetes and stage 1-3b chronic kidney disease as reasonable and necessary, the company said. The...
Home Depot says Hart-Scott-Rodino Act Waiting Period Expires on SRS Acquisition
Home Depot says Hart-Scott-Rodino Act Waiting Period Expires on SRS Acquisition
Jun 14, 2024
08:26 AM EDT, 06/14/2024 (MT Newswires) -- Home Depot ( HD ) said Friday that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for its acquisition of SRS Distribution expired on June 13. The expiration of the waiting period satisfies an important condition necessary for the completion of the transaction, which is expected to occur on June...
George Weston Enters Automatic Share Purchase Plan
George Weston Enters Automatic Share Purchase Plan
Jun 14, 2024
08:20 AM EDT, 06/14/2024 (MT Newswires) -- George Weston (WN.TO) said on Friday that it entered into an automatic share purchase plan with a broker for the repurchase of the company's common shares under its previously announced normal course issuer bid. The Toronto Stock Exchange allowed the company to buy up to 6.6 million common shares, representing about 5% of...
TScan Therapeutics Names Stephen Biggar Board Chair
TScan Therapeutics Names Stephen Biggar Board Chair
Jun 14, 2024
08:27 AM EDT, 06/14/2024 (MT Newswires) -- TScan Therapeutics ( TCRX ) said Friday that Stephen Biggar has been appointed chair of the board of directors. Biggar, who has served on the company's board since 2021, will succeed Timothy Barberich, who has retired, according to the company. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved